Eosinophil and Anticoagulation in COVID-19 Patients

Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04507282

Enrollment

Registered

2020-08-11

Start date

2020-05-15

Completion date

2020-07-15

Last updated

2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Interventions

DRUGLMWH

COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH, * agreed to participate in the study were included

Exclusion criteria

* Patients with previous coagulopathy, * continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease), * glomerular filtration rate (GFR) \<30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
subprophylactic anticogulation level	14 days	\<0.2IU/ml

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026